Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway

Invention Grant

US10201615B2 Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway 有权

Please log in to see more content

Patent Title: Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
Application No.: US15008365

Application Date: 2016-01-27
Publication No.: US10201615B2

Publication Date: 2019-02-12
Inventor: Timothy S. Lewis , Che-Leung Law , Julie A. McEarchern
Applicant: Seattle Genetics, Inc.
Applicant Address: US WA Bothell
Assignee: SEATTLE GENETICS, INC.
Current Assignee: SEATTLE GENETICS, INC.
Current Assignee Address: US WA Bothell
Agency: Alston & Bird LLP
Main IPC: A61K47/48
IPC: A61K47/48 ; A61K31/436 ; A61K45/06 ; A61K31/4375 ; A61K31/4745 ; A61K31/498 ; A61K31/519 ; A61K31/5377 ; A61K39/395

Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway

Abstract:

The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.

Public/Granted literature

US20160220693A1 SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY Public/Granted day:2016-08-04

Information query

Espacenet